삼성서울병원

Ko En

방사선종양학과 표홍렬 교수

진료분야
폐암, 비뇨기암, 특수방사선치료
진료일정 04 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
오전
오후
진료일정 05 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
오전
오후

학력

학력
2005.08 충남대학교 의과대학원 졸업 (박사)
1994.08 연세대학교 의과대학원 졸업 (석사)
1990.02 연세대학교 의과대학교 졸업 (학사)

경력

경력
2019.04 ~현재 삼성서울병원 방사선종양학과장
2019.04 ~현재 삼성서울병원 암병원 데이터관리 팀장
2019.04 ~현재 성균관의대 방사선종양학교실 주임교수
2010.02 ~현재 삼성서울병원 방사선종양학과 교수
2017.04 ~ 2019.03 삼성서울병원 암병원 양성자치료센터장
2012.06 ~ 2014.05 University Of North Carolina 방문연구교수
2003.03 ~ 2010.01 국립암센터 양성자치료센터 전문의
2001.03 ~ 2003.02 세브란스병원 방사선종양학과 조교수
1998.11 ~ 2001.02 Vanderbilt University Research Fellow
1998.05 ~ 1998.10 세브란스병원 방사선종양학과 임상강사
1991.03 ~ 1995.02 세브란스병원 방사선종양학과 레지턴트
1990.03 ~ 1991.02 세브란스병원 인턴

학회활동

학회활동
2015.10 ~ 2017.09 대한방사선종양학회 총무이사
  • Int J Chron Obstruct Pulmon Dis 2019 10.2147/COPD.S210759 Impact Of Underlying Pulmonary Diseases On Treatment Outcomes In Early-Stage Non-Small Cell Lung Cancer Treated With Definitive Radiotherapy Kim1, H; Yoo, H; Pyo, H; Ahn, YC; Noh, JM; Ju, SG; Lee, W; Park, B; Kim, JM; Kang, N; Shin, SH; Chung, MP; Shin, S; Kim, HS; Park, M; Park, HY
    View PubMed
  • J RADIAT RES 2019 10.1093/jrr/rrz040 Role of prophylactic cranial irradiation for elderly patients with limited-disease small-cell lung cancer: inverse probability of treatment weighting using propensity score Kim1, TG; Pyo, H; Ahn, YC; Noh, JM; Oh, D
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.366 Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer Lee1, KH; Ahn, YC; Pyo, H; Noh, JM; Park, SG; Kim, TG; Lee, E; Nam, H; Lee, H; Sun, JM; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.125 EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy Park1, SE; Noh, JM; Kim, YJ; Lee, HS; Cho, JH; Lim, SW; Ahn, YC; Pyo, H; Choi, YL; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J RADIAT RES 2019 10.1093/jrr/rry102 Concurrent chemo-radiotherapy for unresectable non-small cell lung cancer invading adjacent great vessels on radiologic findings: is it safe? Yoo1, GS; Oh, D; Pyo, H; Ahn, YC; Noh, JM; Park, HC; Lim, DH
    View PubMed
  • RADIAT ONCOL 2019 10.1186/s13014-019-1221-4 Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy Kim1, H; Pyo, H; Noh, JM; Lee, W; Park, B; Park, HY; Yoo, H
    View PubMed
  • PHYS MEDICA 2018 10.1016/j.ejmp.2018.10.009 Investigations of line scanning proton therapy with dynamic multi-leaf collimator Kim1, DH; Park, S; Jo, K; Cho, S; Shin, E; Lim, DH; Pyo, H; Han, Y; Suh, TS
    View PubMed
  • Journal of thoracic disease 2018 10.21037/jtd.2018.04.127 The more and the heavier may not always be an answer Pyo1, H; Lee, SH; Kim, J
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2017.11.020 Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer Lee1, J; Kim, HK; Park, BJ; Cho, JH; Choi, YS; Zo, JI; Shim, YM; Pyo, H; Ahn, YC; Ahn, JS; Ahn, MJ; Park, K; Kim, J
    View PubMed
  • J THORAC ONCOL 2017 10.1016/j.jtho.2017.09.1954 Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer Sun1, JM; Noh, JM; Oh, D; Kim, HK; Lee, SH; Choi, YS; Pyo, H; Ahn, JS; Jung, SH; Ahn, YC; Kim, J; Ahn, MJ; Zo, JI; Shim, YM; Park, K
    View PubMed
  • RADIAT ONCOL 2017 10.1186/s13014-017-0905-x Normal lung sparing Tomotherapy technique in stage III lung cancer Hong1, CS; Ju, SG; Ahn, YC; Yoo, GS; Noh, JM; Oh, D; Chung, K; Pyo, H; Jo, K
    View PubMed
  • CANCER RES TREAT 2017 10.4143/crt.2016.442 Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience Park1, H; Oh, D; Ahn, YC; Pyo, H; Noh, JM; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Kim, HK; Choi, YS; Kim, J; Zo, JI; Shim, YM
    View PubMed
  • Sci Rep. 2017 Jan 19;7:40922. doi: 10.1038/srep40922. Development of patient-specific phantoms for verification of stereotactic body radiation therapy planning in patients with metallic screw fixation Oh D11, Hong CS1, Ju SG1, Kim M1, Koo BY1, Choi S1, Park HC1, Choi DH1, Pyo H1.
    View PubMed
  • J Thorac Oncol. 2016 Dec;11(12):2202-2207. doi: 10.1016/j.jtho.2016.07.005. Epub 2016 Jul 14. Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease? Kim H11, Ahn YC2, Pyo H1, Oh D1, Noh JM1, Sun JM3, Ahn JS3, Ahn MJ3, Park K3, Choi YS4, Kim J4, Zo JI4, Shim YM4, Lee M5, Han J5.
    View PubMed
  • Cancer Res Treat. 2016 Oct;48(4):1187-1195. Epub 2016 Mar 9. Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules Cho WK11, Noh JM1, Ahn YC1, Oh D1, Pyo H1.
    View PubMed
  • Strahlenther Onkol. 2016 Sep;192(9):649-57. doi: 10.1007/s00066-016-0985-9. Epub 2016 Jun 9. Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas Lee SU11, Moon SH2,3,4, Cho KH1, Pyo HR5, Kim JY1, Kim DY1, Kim TH1, Suh YG1, Kim YJ1.
    View PubMed
  • Cancer Res Treat. 2016 Jan;48(1):106-14. doi: 10.4143/crt.2014.131. Epub 2015 Feb 12. Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy Noh JM11, Kim JM1, Ahn YC1, Pyo H1, Kim B1, Oh D1, Ju SG1, Kim JS1, Shin JS1, Hong CS1, Park H1, Lee E1.
    View PubMed
  • Cancer Res Treat. 2015 Oct;47(4):645-52. doi: 10.4143/crt.2014.144. Epub 2015 Feb 12. Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer Noh JM11, Ahn YC1, Lee H2, Pyo H1, Kim B1, Oh D1, Park H1, Lee E1, Park K3, Ahn JS3, Ahn MJ3, Sun JM3.
    View PubMed
  • 없음 Radical prostatectomy versus external beam radiotherapy for localized prostate cancer Comparison of treatment outcomes
  • Int J Urol. 2015 Jan;22(1):82-7. doi: 10.1111/iju.12604. Epub 2014 Sep 10. Significance of early prostate-specific antigen values after salvage radiotherapy in recurrent prostate cancer patients treated with surgery Chang JH11, Park W, Park JS, Pyo H, Huh SJ, Choi HY, Lee HM, Jeon SS, Seo SI.
    View PubMed
  • Ann Surg Oncol. 2014 Jun;21(6):2083-90. doi: 10.1245/s10434-014-3540-x. Epub 2014 Feb 13. Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy Lee H11, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM.
    View PubMed
  • Radiother Oncol. 2014 Feb;110(2):240-4. doi: 10.1016/j.radonc.2014.01.001. Epub 2014 Jan 28. Suggestion for the prostatic fossa clinical target volume in adjuvant or salvage radiotherapy after a radical prostatectomy Park JS11, Park W2, Pyo HR1, Park BK3, Park SY3, Choi HY4, Lee HM4, Jeon SS4, Seo SI4, Jeong BC4, Jeon HG4.
    View PubMed
  • J Radiat Res. 2013 Nov 1;54(6):1036-42. doi: 10.1093/jrr/rrt066. Epub 2013 May 22. Involvement of inducible nitric oxide synthase in radiation-induced vascular endothelial damage Hong CW11, Kim YM, Pyo H, Lee JH, Kim S, Lee S, Noh JM.
    View PubMed
  • Acta Oncol.?2013 Apr;52(3):477-85. doi: 10.3109/0284186X.2013.764011. Epub 2013 Feb 11. A phase II study of hypofractionated proton therapy for prostate cancer Kim YJ11,?Cho KH,?Pyo HR,?Lee KH,?Moon SH,?Kim TH,?Shin KH,?Kim JY,?Lee SB,?Nam BH.
    View PubMed
  • Cancer Biother Radiopharm. 2013 Mar;28(2):138-45. doi: 10.1089/cbr.2012.1264. Epub 2012 Dec 26. Different Cell Cycle Modulation by Celecoxib at Different Concentrations Kim YM11, Pyo H.
    View PubMed
  • Strahlenther Onkol. 2012 Oct;188(10):901-9. Epub 2012 Aug 17. Superiority of conventional intensity-modulated radiotherapy over helical tomotherapy in locally advanced non-small cell lung cancer A comparative plan analysis Song C11, Pyo H, Kim J, Lim YK, Kim WC, Kim HJ, Kim DW, Cho KH.
    View PubMed
  • Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e399-407. doi: 10.1016/j.ijrobp.2012.01.001. Epub 2012 Mar 13. Celecoxib Enhances the Radiosensitizing Effect of 7-Hydroxystaurosporine (UCN-01) in Human Lung Cancer Cell Lines Kim YM11, Jeong IH, Pyo H.
    View PubMed
  • DNA Cell Biol. 2012 Jan;31(1):15-29. doi: 10.1089/dna.2011.1342. Epub 2011 Aug 10. Cooperative Enhancement of Radiosensitivity After Combined Treatment of 17-(Allylamino)-17-Demethoxygeldanamycin and Celecoxib in Human Lung and Colon Cancer Cell Lines Kim YM11, Pyo H.
    View PubMed
  • J Radiat Res. 2011;52(6):752-65. Systematic Analyses of Genes Associated with Radiosensitizing Effect by Celecoxib, a Specific Cyclooxygenase-2 Inhibitor Kim YM11, Shin YK, Jun HJ, Rha SY, Pyo H.
    View PubMed
  • Med Dosim. 2011 Autumn;36(3):299-305. doi: 10.1016/j.meddos.2010.05.005. Epub 2010 Oct 23. PROTON RANGE UNCERTAINTY DUE TO BONE CEMENT INJECTED INTO THE VERTEBRA IN RADIATION THERAPY PLANNING Lim YK11, Hwang UJ, Shin D, Kim DW, Kwak J, Yoon M, Lee DH, Lee SB, Lee SY, Park SY, Pyo HR.
    View PubMed
  • DNA Cell Biol. 2011 Apr;30(4):219-27. doi: 10.1089/dna.2010.1141. Epub 2011 Feb 7. Ataxia Telangiectasia and Rad3-Related Overexpressing Cancer Cells Induce Prolonged G(2) Arrest and Develop Resistance to Ionizing Radiation Kim YM11, Lee YM, Park SY, Pyo H.
    View PubMed
  • Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):651-8. doi: 10.1016/j.ijrobp.2009.08.068. Epub 2010 Mar 6. TREATMENT-RELATED PNEUMONITIS AND ACUTE ESOPHAGITIS IN NON-SMALL-CELL LUNG CANCER PATIENTS TREATED WITH CHEMOTHERAPY AND HELICAL TOMOTHERAPY: IN REGARD TO SONG ET AL. REPLY Song CH11, Pyo H, Moon SH, Kim TH, Kim DW, Cho KH.
    View PubMed
  • Mol Cancer. 2010 Aug 23;9:222. doi: 10.1186/1476-4598-9-222. Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated Park SY11, Kim YM, Pyo H.
    View PubMed